Craft
Genprex

Genprex

Patents Issued

30

Q2, 2017

Market Capitalization

$67.4 M

2022-09-23

Genprex Summary

Company summary

Overview
Genprex is a gene therapy company developing treatments for cancer and diabetes. Its cancer therapies are based upon a technology platform, including its lead drug candidate, Oncoprex immunogene therapy, or Oncoprex, for non-small cell lung cancer that consists of a tumor suppressor gene inserted into a patient’s cells that has immunomodulatory effects.
Type
Public
Founded
2009
HQ
West Lake Hills, TX, US | view all locations
Website
http://genprex.com
Cybersecurity rating
ESG rating
out of 100 | View all ESG data
Sectors

Key people

  • Rodney Varner

    Rodney Varner, Chairman, President & Chief Executive Officer

  • Catherine M. Vaczy

    Catherine M. Vaczy, Executive Vice President, General Counsel and Chief Strategy Officer

  • Mark Berger

    Mark Berger, Chief Medical Officer

  • Hemant Kumar

    Hemant Kumar, Chief Manufacturing and Technology Officer

    Operating MetricsView all

    Phase I Patients Enrolled

    28

    Q2, 2017

    Patents Issued

    30

    Q2, 2017

    Patent Applications

    2

    Q2, 2017

    LocationsView all

    2 locations detected

    • West Lake Hills, TX HQ

      United States

      3300 Bee Caves Rd 650 227

    • Austin, TX

      United States

      One Congress Plaza, 100 Congress Ave Ste. 2000

    Genprex Financials

    Summary financials

    Net income (Q2, 2022)
    ($5.2M)
    Cash (Q2, 2022)
    $30.1M
    EBIT (Q2, 2022)
    ($5.2M)

    Footer menu